BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence M Xing, R Liu, X Liu, AK Murugan, G Zhu, MA Zeiger, S Pai, J Bishop Journal of clinical oncology 32 (25), 2718, 2014 | 695 | 2014 |
Highly prevalent TERT promoter mutations in aggressive thyroid cancers X Liu, J Bishop, Y Shan, S Pai, D Liu, AK Murugan, H Sun, AK El-Naggar, ... Endocrine-related cancer 20 (4), 603-610, 2013 | 631 | 2013 |
TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer X Liu, S Qu, R Liu, C Sheng, X Shi, G Zhu, AK Murugan, H Guan, H Yu, ... The Journal of Clinical Endocrinology & Metabolism 99 (6), E1130-E1136, 2014 | 332 | 2014 |
mTOR: Role in cancer, metastasis and drug resistance AK Murugan Seminars in cancer biology 59, 92-111, 2019 | 320 | 2019 |
Anaplastic Thyroid Cancers Harbor Novel Oncogenic Mutations of the ALK Gene AK Murugan, M Xing Cancer research 71 (13), 4403-4411, 2011 | 247 | 2011 |
Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas AK Murugan, NT Hong, Y Fukui, AK Munirajan, N Tsuchida International journal of oncology 32 (1), 101-111, 2008 | 162 | 2008 |
Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer AK Murugan, E Bojdani, M Xing Biochemical and biophysical research communications 393 (3), 555-559, 2010 | 149 | 2010 |
Ras oncogenes in oral cancer: the past 20 years AK Murugan, AK Munirajan, N Tsuchida Oral oncology 48 (5), 383-392, 2012 | 126 | 2012 |
Long noncoding RNAs: emerging players in thyroid cancer pathogenesis AK Murugan, AK Munirajan, AS Alzahrani Endocrine-related cancer 25 (2), R59-R82, 2018 | 122 | 2018 |
RAS mutations in human cancers: Roles in precision medicine AK Murugan, M Grieco, N Tsuchida Seminars in cancer biology 59, 23-35, 2019 | 109 | 2019 |
Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer Z Zhang, D Liu, AK Murugan, Z Liu, M Xing Endocrine-Related Cancer 21 (2), 161, 2014 | 97 | 2014 |
Identification of RASAL1 as a Major Tumor Suppressor Gene in Thyroid Cancer D Liu, C Yang, E Bojdani, AK Murugan, M Xing Journal of the National Cancer Institute 105 (21), 1617-1627, 2013 | 97 | 2013 |
MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas AK Murugan, J Dong, J Xie, M Xing Cell cycle 8 (13), 2122-2124, 2009 | 94 | 2009 |
TERT Promoter Mutations in Thyroid Cancer AS Alzahrani, R Alsaadi, AK Murugan, BB Sadiq Hormones and Cancer 7, 165-177, 2016 | 91 | 2016 |
APOBEC: A molecular driver in cervical cancer pathogenesis S Revathidevi, AK Murugan, H Nakaoka, I Inoue, AK Munirajan Cancer letters 496, 104-116, 2021 | 85 | 2021 |
Genetic deregulation of the PIK3CA oncogene in oral cancer AK Murugan, AK Munirajan, N Tsuchida Cancer letters 338 (2), 193-203, 2013 | 70 | 2013 |
Kirsten Ras oncogene: significance of its discovery in human cancer research N Tsuchida, AK Murugan, M Grieco Oncotarget 7 (29), 46717, 2016 | 69 | 2016 |
Dysregulation of miR-200 family microRNAs and epithelial-mesenchymal transition markers in oral squamous cell carcinoma G Arunkumar, AK Deva Magendhra Rao, M Manikandan, ... Oncology letters 15 (1), 649-657, 2018 | 64 | 2018 |
Single point mutations in pediatric differentiated thyroid cancer AS Alzahrani, AK Murugan, E Qasem, M Alswailem, H Al-Hindi, Y Shi Thyroid 27 (2), 189-196, 2017 | 60 | 2017 |
Serum sonic hedgehog (SHH) and interleukin-(IL-6) as dual prognostic biomarkers in progressive metastatic breast cancer AS Noman, M Uddin, AA Chowdhury, MJ Nayeem, Z Raihan, MI Rashid, ... Scientific reports 7 (1), 1796, 2017 | 54 | 2017 |